Search Result

Results for "

STEAP1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Antibody-Drug Conjugates (ADCs) (1) CD3 (1) Epigenetic Reader Domain (3) Mitosis (1) PROTAC-Linker Conjugates for PAC (1) PROTACs (3) Small Interfering RNA (siRNA) (4) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (6)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (4)

Inhibitors & Agonists

Inhibitory Antibodies

Recombinant Proteins

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P990688

Xaluritamig AMG-509	CD3	Cancer
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a K_d of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to *STEAP1* via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and *STEAP1*-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 ⁺ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low *STEAP1* expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in *STEAP1×CD3* XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma ^[1] .

HY-P990673

Vandortuzumab DSTP-3086S Antibody; RG-7450 Antibody	ADC Antibody Transmembrane Glycoprotein Mitosis	Cancer
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to *STEAP1* and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC) ^[1] .

HY-138632

PROTAC BRD4 Degrader linker conjugate	PROTACs Epigenetic Reader Domain PROTAC-Linker Conjugates for PAC	Cancer
PROTAC BRD4 Degrader linker conjugate is a linker-payload conjugate as well as a bifunctional degrader of BRD4 that binds to VHL, consisting of PROTAC and a linker. PROTAC BRD4 Degrader linker conjugate can be conjugated with STEAP1 and CLL1 antibodies to degrade BRD4 protein, with DC₅₀ values of 0.86 nM and 7.6 nM, respectively. PROTAC BRD4 Degrader linker conjugate can be used in research related to prostate cancer and acute myeloid leukemia (BRD4 ligand: (HY-129939); VHL ligand: (HY-125845)) ^[1].\n

HY-RS13905

STEAP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
STEAP1 Human Pre-designed siRNA Set A contains three designed siRNAs for STEAP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

STEAP1 Human Pre-designed siRNA Set A STEAP1 Human Pre-designed siRNA Set A

HY-RS16998

Steap1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Steap1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Steap1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Steap1 Mouse Pre-designed siRNA Set A Steap1 Mouse Pre-designed siRNA Set A

HY-RS23441

Steap1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Steap1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Steap1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Steap1 Rat Pre-designed siRNA Set A Steap1 Rat Pre-designed siRNA Set A

HY-138633

PROTAC BRD4 Degrader-10	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-10 (compound 8b) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-10 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC₅₀ of 1.3 nM and 18 nM, respectively ^[1].

HY-138635

PROTAC BRD4 Degrader-12	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-12 (compound 9c) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-12 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC₅₀ of 0.39 nM and 0.24 nM, respectively ^[1].

HY-P99528

Vandortuzumab vedotin DSTP 3086S; RG 7450; MSTP2109A	Antibody-Drug Conjugates (ADCs)	Cancer
Vandortuzumab vedotin (DSTP 3086S; RG 7450) is a *STEAP1*-targeted antibody-drug conjugate (ADC). Vandortuzumab vedotin binds specifically to *STEAP1*, triggers internalization of the conjugate complex, mediates intracellular release of monomethyl auristatin E, inhibits cell division, and induces cell death. Vandortuzumab vedotin exhibits antitumor activity in preclinical prostate cancer xenografts. Vandortuzumab vedotin can be used for the research of metastatic castration-resistant prostate cancer ^[1].

HY-RS13906

STEAP1B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
STEAP1B Human Pre-designed siRNA Set A contains three designed siRNAs for STEAP1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

STEAP1B Human Pre-designed siRNA Set A STEAP1B Human Pre-designed siRNA Set A

Cat. No.	Product Name	Target	Research Area	Image

HY-P990688

Xaluritamig AMG-509	CD3	Cancer
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a K_d of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to *STEAP1* via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and *STEAP1*-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 ⁺ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low *STEAP1* expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in *STEAP1×CD3* XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma ^[1] .

HY-P990673

Vandortuzumab DSTP-3086S Antibody; RG-7450 Antibody	ADC Antibody Transmembrane Glycoprotein Mitosis	Cancer
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to *STEAP1* and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC) ^[1] .

HY-P99528

Vandortuzumab vedotin DSTP 3086S; RG 7450; MSTP2109A	Antibody-Drug Conjugates (ADCs)	Cancer
Vandortuzumab vedotin (DSTP 3086S; RG 7450) is a *STEAP1*-targeted antibody-drug conjugate (ADC). Vandortuzumab vedotin binds specifically to *STEAP1*, triggers internalization of the conjugate complex, mediates intracellular release of monomethyl auristatin E, inhibits cell division, and induces cell death. Vandortuzumab vedotin exhibits antitumor activity in preclinical prostate cancer xenografts. Vandortuzumab vedotin can be used for the research of metastatic castration-resistant prostate cancer ^[1].

Species:	Rat (1) Mouse (1)
Tag:	His (2)
Source:	E. coli Cell-free (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702448

	STEAP1 Protein, Mouse (Cell-Free, His) Metalloreductase STEAP1; Six-transmembrane epithelial antigen of prostate 1	Mouse	E. coli Cell-free
	The STEAP1 protein is classified as a member of the metal reductase family and cannot function as a functional metal reductase, mainly due to the lack of binding sites for the electron-donating substrate NADPH. This unique feature distinguishes STEAP1 from typical metal reductases, which are characterized by their ability to catalyze the reduction of metal ions using NADPH as an electron donor. STEAP1 Protein, Mouse (Cell-Free, His) is the recombinant mouse-derived STEAP1 protein, expressed by E. coli Cell-free , with C-10*His labeled tag.

HY-P702449

	STEAP1 Protein, Rat (Cell-Free, His) STEAP family member 1	Rat	E. coli Cell-free
	The STEAP1 protein is classified as a member of the metal reductase family and cannot function as a functional metal reductase, mainly due to the lack of binding sites for the electron-donating substrate NADPH. This unique feature distinguishes STEAP1 from typical metal reductases, which are characterized by their ability to catalyze the reduction of metal ions using NADPH as an electron donor. STEAP1 Protein, Rat (Cell-Free, His) is the recombinant rat-derived STEAP1 protein, expressed by E. coli Cell-free , with C-10*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

STEAP1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
STEAP1 Human Pre-designed siRNA Set A contains three designed siRNAs for STEAP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Steap1 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Steap1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Steap1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Steap1 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Steap1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Steap1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

STEAP1B Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
STEAP1B Human Pre-designed siRNA Set A contains three designed siRNAs for STEAP1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.